@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter (Portuguese Version)
@OncEd Presents Dr. Ramon Andrade de Mello – Hypermethylation of the TERT Promoter
@OncEd Presents Dr. Silke Gillessen – SAKK 08/11 Study
@OncEd Presents Dr. Vladimir Milovanov – Predicting incomplete cytoreduction and aborted HIPEC in PC
@OncEd Presents Dr. Juan Pablo Marquez Manriquez – Multi-Antigen Vaccination for Colon Cancer Treatment and Prevention
@OncEd Presents Dr. Sunil Verma – ECC 2015 Breast Cancer Updates
@OncEd Presents Dr. Jeff Weber – Novel Combinations with Checkpoint Inhibitors
@OncEd Presents Dr. Stephen Doral Stefani – Access and Equity
@OncEd Presents Dr. Wolfgang Janni – DETECT Study
@OncEd Presents Dr. Jean Fayette – UNICANCER Trial
@OncEd Presents Dr Michael Untch – GEPARQUINTO Study
@OncEd Presents Dr. Fernando Rivera – PEAK Trial
At the European Cancer Congress (ECC) 2015, Mark Lawler, PhD, of Queens University Belfast, Belfast, UK, Richard Sullivan, MD, PhD,…
In patients with early stage breast cancer, there is a need to identify prognostic factors to determine the risk of…
@OncEd Presents Dr. Christos Sotiriou – NEOALTTO Trial
@OncEd Presents Dr. Linda Lindstrom – ST03 Trial
@OncEd Presents Dr. Neal Shore – TAK-385 Trial
@OncEd Presents Visualization and relaxation as anxiety reducing techniques – Dr. Andreas Charalambous. From ECC 2015 in Vienna, Austria.
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses…
At the European Cancer Congress (ECC) 2015, Giorgio V. Scagliotti, MD, PhD, of the University of Turin, Turin, Italy, discusses…
Dr Naughton discusses challenges facing women who are evaluating extention of adjuvant endocrine treatment and how he finds Breast Cancer…
At the European Cancer Congress (ECC) 2015, Peter Naredi, MD, PhD, of the University of Gothenburg, Gothenburg, Sweden, chairs a…
European Cancer Patient Coalition (ECPC) is the largest European cancer patients’ umbrella organisation, representing 365 patient organisations in 40 European…
There is a growing divide in cancer healthcare and survivorship between populations across Europe. European Cancer Patient Coalition (ECPC), the…
At the European Cancer Congress (ECC) 2015, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, discusses…
European Cancer Patient Coalition (ECPC), the largest European cancer patients umbrella organisation, presented the paper, Europe of Disparities in Cancer,…
A meta-analysis was conducted to include 12 randomised trials and a total of 1,231 breast cancer patients receiving chemotherapy, with…
Genomic interventions may improve disease-risk stratification and patient-tailored treatment. At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA,…
At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincents University Hospital, Dublin, Ireland, discusses the…
Results from a study in The Netherlands involving 13,715 patients showed that aspirin use after a cancer diagnosis significantly improved…
Updated results from the phase 3 COMBI-v trial of a combination of dabrafenib and trametinib for the first-line treatment of…
Genetic analysis of biopsies taken from the primary tumour, brain metastases and normal tissues of 104 adults with cancer found…
At the European Cancer Congress (ECC) 2015, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute UK, London, UK, discusses…
At the European Cancer Congress (ECC) 2015, Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, New York, NY,…
NETTER-1, a phase 3 clinical trial, evaluated Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in patients with Grade 12 metastatic…
RADIANT-4, a placebo-controlled, double-blind, phase 3 clinical trial conducted in centres in 13 European countries, Korea, Japan, Canada, and the…
The European Society for Paediatric Oncology (SIOP Europe or SIOPE), is a pan-European organisation that represents professionals working in the…
At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet,…
CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment,…
Comparisons of cancer patients survival and care in Europe up to 2007 showed that although more patients are surviving for…
METEOR, a phase 3 clinical trial, compared cabozantinib, a novel receptor tyrosine kinase inhibitor, with everolimus for the treatment of…
The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle…
Dr. Hamilton appeared on Fox & Friends to discuss a new treatment option for HER2+ breast cancer, an aggressive form…
Dr. Bendell appeared on MSNBC to discuss former U.S. president Jimmy Carter’s melanoma diagnosis. Dr. Bendell discusses breakthroughs in treatment…
Dr. John Hainsworth of the Sarah Cannon Research Institute explains the different types of non-Hodgkin’s lymphoma.
Dr. Skip Burris on This Hour with Berman and Michael on CNN discussing cancer research in 2014.
Our physician experts appeared on Fox and Friends on 4/29 to discuss exciting new developments on the war on cancer.…
Dr. David Spigel on @FoxNews discussing exciting developments in #immunotherapy at the Annual ASCO Meeting
Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute,…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and…
Saad Z. Usmani, MD Levine Cancer Institute – Morehead Charlotte, North Carolina, USA SWOG 1211: A randomized phase I/II study…
Henk Lokhorst, MD University Medical Center Utrecht Utrecht, the Netherlands Dose-dependent efficacy of daratumumab (DARA) as monotherapy in patients with…
Gunjan L. Shah, MD Tufts Medical Center Oncology Boston Massachusetts, USA Survival benefit and cost of autologous hematopoietic stem cell…
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA MM-014: A phase 2 trial evaluating efficacy, safety, and…
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase 1 (Ph1) trial of MK-3475 combined with…
David Siegel, MD John Theurer Cancer Center Hackensack, New Jersey, USA A phase I study of carfilzomib, lenalidomide, vorinostat, and…
David Siegel, MD John Theurer Cancer Center Hackesack, New Jersey, USA Phase 1-2 open-label, multiple-dose, dose-escalation study to evaluate the…
Torben Plesner, MD Department of Hematology, Vejle Hospital Vejle, Denmark Daratumumab (DARA) (HuMax-CD38), a human IgG1? monoclonal antibody effectively mediates…
Matthias Weiss, MD Marshfield Clinic Marshfield, Wisconsin, USA ECOG multiple myeloma (MM) clinical trial (CT) accrual performance evaluation utilizing the…
Jeremy Larsen, MD Mayo Clinic Rochester, Minnesota, USA Free light chain assay and cytogenetic abnormalities for identification of high-risk smoldering…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA MM-005: Phase 1 trial of pomalidomide (POM), bortezomib (BORT), and low-dose…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and…
Paul Richardson, MD Dana-Farber Cancer Institute Boston, Massachusetts, USA DETERMINATION trial: A phase III multi-center study examining the timing of…
Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone…
Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone…
Charlotte Pawlyn, MD Institute of Cancer Research Sutton, United Kingdom Treatment with immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) has…
Angela Dispenzieri, MD Mayo Clinic Rochester, Minnesota, USA Remission of Disseminated Cancer After Systemic Oncolytic Virotherapy (n.b., using modified measles…
Xin Shelley Wang, MD MD Anderson Cancer Center Houston, Texas, USA Prevalence of high symptom burden and its impact on…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Mohammed Jaloudi, MD, of Tawam Hospital, Al Ain, United…
Saad Z. Usmani, MD Levine Cancer Institute – Morehead Charlotte, North Carolina, USA Continuous lenalidomide (LEN) therapy versus observation following…
Thomas G. Martin, MD University of California SF San Francisco, California, USA A phase Ib dose escalation trial of SAR650984…
James R. Berenson, MD Institute for Myeloma & Bone Cancer Research West Hollywood, California, USA Results of the dose-escalation portion…
Thomas G. Martin, MD University of California SF San Francisco, California, USA A phase I trial of SAR650984, a CD38…
Antonio Palumbo, MD University of Torino Torino Italy Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed…
Keith K. Stewart, MB ChB Mayo Clinic Scottsdale, Arizona, USA E1A06: A phase III trial comparing melphalan, prednisone, and thalidomide…
Mark A. Fiala, BS, CCRN Washington University School of Medicine Division of Oncology, Department of Medicine Saint Louis, MO, USA…
Dr. Paul Richardson Dana-Farber Cancer Institute Boston, Massachusetts, USA Visit our website at: http://www.myeloma.org
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hope S. Rugo, MD, of the UCSF Helen Diller…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Dr. Durie talks about the Black Swan Research Initiative Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+:…
Nurse Leadership Board Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma)…
Nurse Leadership Board #1 Cont. Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter:…
Nurse Leadership Board Visit our website at: http://www.myeloma.org Find us online: Facebook: http://facebook.com/myeloma Google+: http://gplus.to/imfmyeloma IMF on twitter: @IMFMyeloma (http://twitter.com/imfmyeloma)…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS…
Since 2003, the IMF has honored an outstanding physician each year with the Robert A. Kyle Lifetime Achievement Award. The…
The International Myeloma Foundation (IMF) and the EuroFlow consortium introduce a new automated and highly sensitive flow cytometry method for…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive…
BRCA1 and 2 mutation carriers: breast cancer and more. Dr Shani Paluch-Shimon (Israel) discusses the topic with Dr Fedro A.…
HPV vaccination for cervical cancer: times they are a-changing. Dr Xavier Bosch (Spain) explains the effectiveness of HPV vaccination. Discussion…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Keith Kerr, BSc, MB, ChB, FRCPath, FRCPE, of the…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif,…
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola…
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola…
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola…
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Drs. Brian Durie, Joseph Mikhael, Ola…
IMWG Myeloma Experts debate the latest trends in treatment June 10, 2015 Vienna Austria Visit our website at: http://www.myeloma.org Find…
In this week’s video, Dr. Brian Durie discusses Selinexor, a novel, orally administered drug that is currently ongoing clinical trials.…
In this weeks video, Dr. Brian Durie gives an update on the IMFs signature research project, Black Swan Research Initative.…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the interim analysis of the…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, FASCO, of the University…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of an analysis…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University…
Learn more about current trends in myeloma treatment and research with this update from three major medical meetings held in…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina,…
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas…
At the 14th St. Gallen International Breast Cancer Conference 2015, Masakazu Toi, MD, PhD, of Kyoto University, Japan, explains that…
Dr. Boccia talks about the importance of controlling costs in the current environment and how the bioT3 testing approach can…
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure…
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the…
At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University,…
Kidney Test
Dr. Geo Espinosa of NYU Langone Medical Center talks about the holistic approach in patient care in Integrative Urology which…
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the importance of using a clinically validated test such as…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, of Mayo Clinic, Arizona, TX,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Karim Fizazi, MD, PhD, of the Institut Gustave Roussy,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, discusses the results of a phase…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lisa A. Carey, MD, of the University of North…
Liquid biopsies (also called serum testing) is a practice already approved in Europe for EGFR lung cancer patients. Drawing blood…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jeremy S. Abramson, MD, of the Massachusetts General Hospital…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M.…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Lodovico Balducci, MD, of Moffitt Cancer Center, Tampa, FL,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Paolo A. Ascierto, MD, of Istituto Nazionale Tumori IRCCS…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles. MBBS, MRCP, MD, of Barts Cancer Institute,…
The results of the Oncotype DX® Breast Cancer Assay are reported as a Recurrence Score® a number ranging from 0…
Dr Susan K. Boolbol talks about the importance of objective evidence provided by the Breast Cancer Index (BCI) in treatment…
Dr. Boccia describes cases in which he uses CancerTYPE ID in his clinical practice. For more information, visit: http://www.cancertypeid.com
At the 9th European Breast Cancer Conference (EBCC), Matti Aapro, MD, of Clinique de Genolier, Genolier, Switzerland, and Daniel Rea,…
Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, disusses the results of the CheckMate 067 trial, a phase…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Eleni Efstathiou, MD, PhD, of The University of Texas…
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, explains the Oncotype DX® Breast…
Anne Armstrong, MRCP, PhD, MB ChB, BSc(Hons), of The Christie Hospital, Manchester, UK, and Nigel Bundred, MD, FRCS, of The…
Hope S. Rugo, MD, of UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, shares her experience on the…
Dr. Boccia compares CancerTYPE ID to other gene expression tests and reviews studies validating its accuracy and clinical utility. For…
Dr Stephen C. Malamud and Dr Susan K. Boolbol consider the clinical utility of the Breast Cancer Index (BCI) as…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Nicholas Turner, MD, PhD, of the Institute of Cancer…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sumanta K. Pal, MD, of City of Hope Comprehensive…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of…
Ola Landgren, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, reviews the new data presented at the…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, elected ASCO President for the 20152016 term, Julie M.…
Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss the circumstances in which they would use the Breast Cancer…
Dr. Boccia describes the components of the bioT3 platform and its clinical utility in identifying tumor type and actionable targets…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Caroline Robert, MD, PhD, of Institut Gustave Roussy, Villejuif,…
Jacqueline Barrientos, MD, summarises recent progress in the treatment of chronic lymphocytic leukaemia at the 2015 American Society of Clinical…
Axel Hauschild, MD, of University of Schleswig-Holstein, Kiel, Germany, reviews the clinical trial data for new treatments in melanoma presented…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Georgina Long, BSc, PhD, MBBS, FRACP, of the University…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Andrew B. Lassman, MD, of Columbia University Medical Center,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium,…
Michael J. Mauro, MD, provides a summary of the SIMPLICITY trial. For more information, tools, resources and CE activities please…
Stuart L. Goldberg, MD provides CML meeting highlights live from the 2015 ASCO Annual Meeting that significantly impact practice. For…
Dr. Karen Seiter discusses the efficacy and safety considerations in using ponatinib. For more information, tools, resources and CE activities…
Dr. Karen Seiter discusses the most common reasons for treatment failur For more information, tools, resources and CE activities please…
Dr. Karen Seiter discusses using second-generation TKIs as a first-line approach. For more information, tools, resources and CE activities please…
Dr. Karen Seiter explains how to recognize treatment failure or treatment resistance in CML patients. For more information, tools, resources…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, of The Royal Marsden, London,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Geoffrey R. Oxnard, MD, of Dana-Farber Cancer Institute, Boston,…
Is there a role for second-line therapy in advanced pancreatic cancer? For more information, tools, resources and CE activities please…
Dr. Koushik Das discusses the type of patients that would benefit from pancreatic cancer screening. For more information, tools, resources…
Dr. Koushik Das discusses screening tests and predictive biomarkers for pancreatic cancer. For more information, tools, resources and CE activities…
Dr. Jill Lacy discusses radiotherapy in the treatment of pancreatic cancer, how its role is evolving in specific settings, and…
Dr. Jill Lacy discusses the development of immune therapies for pancreas cancer, the progress that is being made, and provides…
At the 20th Congress of the European Hematology Association (EHA), Andrew Davies, BSc (Hons), BM (Hons), MRCP, PhD, of the…
At the 20th Congress of the European Hematology Association (EHA), Marek Trn?ný, MD, PhD, of Charles University, Prague, Czech Republic,…
At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany,…
At the 20th Congress of the European Hematology Association (EHA), Paula Cramer, MD, of the University Hospital Cologne, Cologne, Germany,…
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the ClÃnica Universidad de…
At the 20th Congress of the European Hematology Association (EHA), Claire Harrison, MD, DM, FRCP, FRCPath, of Guy’s and St…
Breast Cancer Index (BCI) is a molecular, gene expression-based test uniquely positioned to identify patients best suited for extended endocrine…
Dr. Boccia addresses the problem of unclear diagnoses affecting approximately 15% of newly diagnosed patients with metastatic disease each year…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Ruben A. Mesa, MD, Chair of Hematology at Mayo…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, MarÃa-Victoria Mateos, MD, PhD, of the University Hospital of…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ,…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université…
Patrick I. Borgen, M.D, of the Brooklyn Breast Cancer Center talks about reducing opioids in breast cancer surgery using Bupivacaine
Charles L. Loprinzi, MD, of the Mayo Clinic discusses the management of Hot Flashes using SSRI, Gabapentin, Venlafaxine in patients…
Charles L. Loprinzi, MD, of the Mayo Clinic reviews how Olanzapine Decreases Nausea and Vomiting in Patients With Esophageal, Head…
Charles L. Loprinzi, MD, of the Mayo Clinic talks about scrambler therapy for the treatment of chemotherapy- induced peripheral neuropathy
Hope S. Rugo, MD of the UCSF Medical Center talks about the I-SPY 2 Trial and MK-2206 which shows benefit…
Hope S. Rugo, MD of the UCSF Medical Center discusses numerous trials associated with checkpoint inhibitors in triple negative breast…
Hope S. Rugo, MD of the UCSF Medical Center discusses the state of CDK 4/6 Inhibitors for Patients with HR+/HER-…
Hope S. Rugo, MD of the UCSF Medical Center discusses scalp cooling system which prevented significant hair loss in 70.3%…
Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that…
Maha Hussain, MD of University of Michigan Comprehensive Cancer Center discusses Phase II Androgen Deprivation Therapy with Palbociclib
Maha Hussain, MD of the University of Michigan Comprehensive Cancer Center discusses ETS Gene Fusions as a Predictive Biomarker in…
Robert J. Mayer, MD of Dana-Farber Cancer Institute discusses the results of the TAS-102 Trial for Refractory Metastatic Colorectal Cancer
HOWARD A. “SKIP” BURRIS, III, MD of Sarah Canon discusses the PD-1 Benefit in Progression Free Survival for Non-Small Cell…
Nicholas J. Vogelzang, MD or the University of Illinois discusses the expanded access of Radium-223 for prostate cancer patients
Nicholas J. Vogelzang, MD of the University of Illinois discusses second line bladder cancer and PD-L1 antibody
Nicholas J. Vogelzang, MD of the University of Illinois discusses a new trial Sunitinib v. PD-L1 with Bevacizumab
Nicholas J. Vogelzang, MD of the University of Illinois discusses the state of kidney cancer June 2015
Jason Luke, MD of the University of Chicago discusses Phase III Trial Pembrolizumab is Better Than Ipilimumab for Advanced Melanoma
Jason Luke, MD of the University of Chicago discusses gene expression profiling and immune signatures
Jason Luke, MD, of the University of Chicago discusses the Ipilimumab and Nivolumab Combination Study
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved…
The identification of eight new Growth Factor Independence 1B (GFI1B) variants in families with bleeding and platelet disorders may result…
The phase 3 PERSIST-1 study showed that pacritinib, a selective inhibitor of Janus Kinase 2 (JAK2) and Fms-Like Tyrosine Kinase-3…
The European Treatment Outcome Study (EUTOS) investigated the treatment and treatment outcome of patients with chronic myeloid leukaemia (CML). Data…
In a phase 1b, open-label, dose-escalation, multicentre study of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL), the combination…
ELOQUENT-2, a phase 3, randomised, open-label study of lenalidomide and dexamethasone with or without elotuzumab in patients with relapsed or…
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The…
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses Novel immune checkpoint inhibitors
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University talks about the CheckMate 057 trial in non-squamous and…
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses MET exon 14 splice variants is the oncogenic…
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses the Future for PD pathway inhibitors in NSCLC
SURESH RAMALINGAM, MD of the Winship Cancer Institute of Emory University discusses AZD9291 for T790M mutant EGFR is well tolerated.
LECIA SEQUIST, MD of Massachusetts General Hospital discusses TIGER X – Rociletinib for T790M EGFR mutations.
LECIA SEQUIST, MD of Massachusetts General Hospital answers the question How does Rociletinib differ from 1st generations EGFR TKIs?
LECIA SEQUIST, MD of Massachusetts General Hospital discusses ALK inhibitor Alectinib for NSCLC
This was my interview with Dr. Petros Grivas, GU medical oncologist from the Cleveland Clinic at the 2015 ASCO Annual…
In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive…
A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of…
Data from the Childhood Cancer Survivor Study (CCSS), a retrospective cohort study of children diagnosed with cancer from 19701999 at…
The randomised, double-blind, phase 3 CheckMate 067 trial showed that nivolumab alone or nivolumab plus ipilimumab significantly improved progression-free survival…
LECIA SEQUIST, MD of Massachusetts General Hospital discusses LUX-Lung 8 trial and the role of EGFR inhibitors in Squamous Cell…
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine answers the question Will immunotherapy combination regimens be both beneficial…
RAMASWAMY GOVINDAN, MD of the Washington University School of Medicine discusses the role of systemic adjuvant therapy for resected T2N0…
DAVID ROSS CAMIDGE, MD, PHD discusses what causes mechanism resistance to Rociletinib and AZD929